Under the terms of the deal, ADImmune will use Crucell's virosome technology to produce a virosomal adjuvanted influenza vaccine for the three markets. Additionally, ADImmune will produce influenza antigen, which Crucell may purchase for the production of its vaccine product, Inflexal V. Crucell will obtain a 20% equity stake in ADImmune.
Ronald Brus, Crucell's president and CEO, said: “Inflexal V is a distinguishable product that we intend to expand further into existing and new markets. The future additional supply of antigen from ADImmune will increase our possibilities to do this.”
ADImmune is already employing Crucell's PER.C6 technology to develop and commercialize a vaccine against Japanese encephalitis virus in Taiwan and China.